PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
17.56
Current Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.64. Joel Greenblatt would see extra liquidity as a cushion for downturns.
16.76
Quick Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 1.92. Joel Greenblatt would see a superior short-term safety net.
15.67
Cash Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.79. Joel Greenblatt might see a strategic advantage in crisis periods.
16.23
Interest coverage of 16.23 versus zero Drug Manufacturers - Specialty & Generic median. Walter Schloss would verify if our debt service capacity provides advantages.
2.09
Short-term coverage of 2.09 versus zero Drug Manufacturers - Specialty & Generic median. Walter Schloss would verify if our cash flow management provides advantages.